Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

IMACS Studies

Over the last decade IMACS has undertaken a number of projects aimed at achieving its goals of improving the lives of children and adults who suffer from myositis by discovering better therapies and understanding the causes of these diseases. Central to these efforts have been a number of studies to develop consensus and standards on the conduct and reporting of adult and juvenile myositis investigations, including outcome measures, clinical trial design and classification of patients with myositis. Listed here is information on the studies that IMACS has reviewed and endorsed. Feel free to contact the Lead Investigators to learn more about or participate in these studies.

IMACS Studies(337KB)


Completed IMACS Research Projects

IMACS Project I. Developing and Validating Core Set Measures of Myositis Disease Activity and Damage

Primary Objectives: 
Develop and validate new tools to assess disease activity and damage for patients with adult and juvenile dermatomyositis and polymyositis

Start Date: 2000
Completion Date: 2010

Lead Investigators:

Publications:

  1. Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, Lundberg I, Morrison C, Oakley L, Oakley I, Pilkington C, Vencovsky J, Vincent K, Scott DL, Isenberg DA, Int Myositis Outcome Assessment C. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology. 2001; 40(11):1262-1273. [Pub Med]
  2. Huber AM et al. Validation and clinical significance of the childhood myositis assessment scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum. 2004; 50(5):1595-603. [Abstract]
  3. Isenberg DA et al. International Consensus Outcome Measures for patients with idiopathic inflammatory myopathies: Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology, Oxford, 2004; 43(1): 49-54. [Abstract]
  4. Rennebohm RM et al. Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. Arthritis Rheum. 2004; 51(3):365-70. [Abstract]
  5. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, Miller FW, Rider LG; Juvenile Dermatomyositis Disease Activity Collaborative Study Group. The Cutaneous Assessment Tool (CAT): development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford). 2007 Oct;46(10):1606-11. [Abstract]
  6. Isenberg DA et al. International Consensus Outcome Measures for patients with idiopathic inflammatory myopathies: Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology, Oxford, 2004; 43(1): 49-54. [Abstract]
  7. Huber AH et al. Preliminary validation and clinical meaning of the cutaneous assessment tool (CAT) in juvenile dermatomyositis. Arthritis Rheum. 2008; 59:214-221. [Abstract]
  8. Huber AH et al. Alternative scoring of the cutaneous assessment tool (CAT) in juvenile dermatomyositis: Results using abbreviated formats. Arthritis Rheum. 2008; 59:352-356. [Abstract]
  9. Rider LG et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis using the Myositis Damage Index (MDI). Arthritis Rheum. 2009;60:3425-35. [Abstract]
  10. Lachenbruch PA et al. On determining the effects of therapy on disease damage in non-randomized studies with multiple treatments: a study of juvenile myositis. Communications in Statistics – Theory and Methods. 2009;38:3268-81. [Abstract]
  11. Dugan EM, Huber AM, Miller FW, and Rider LG; Photoessay of the idiopathic inflammatory myopathies. Dermatology Online Journal. 2009;15(2):1. [Abstract] [Dermatology Online Journal]
  12. Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, Miller FW, Hicks JE; Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2010 Apr;62(4):465-72. [Abstract]
  13. Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S118-57. doi: 10.1002/acr.20532. Review. [Abstract]

IMACS Project II. Determining Clinically Meaningful Change in Core Set Activity Measures and Developing Preliminary Definitions of Improvement

Primary Objectives: 

  1. Determine clinically meaningful change in core set activity measures
  2. Develop preliminary definitions of improvement as response criteria for adult and juvenile dermatomyositis and polymyositis

Start Date: 2002
Completion Date: 2004

Lead Investigators: 

Publications: 

  1. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, Lachenbruch PA, Miller FW. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004; 50(7):2281-90. [Abstract] [Full Text]
  2. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, Lachenbruch PA, Miller FW; International Myositis Assessment and Clinical Studies Group. Defining Clinical Improvement in Adult and Juvenile Myositis. J Rheumatol. 2003 Mar;30(3):603-17. [Abstract]

IMACS Project III. Consensus Guidelines for the Design and Conduct of Myositis Clinical Trials

Primary Objectives:
Develop consensus in the design of myositis clinical trials, including classification criteria for myositis.

Start Date: 2002
Completion Date: 2005

Lead Investigators:

Publications:

  1. Oddis CV et al. International consensus guidelines for therapeutic trials in the idiopathic inflammatory myopathies. Arthritis Rheum. 2005; 52(9):2607-2615. [Abstract]

IMACS Project IV. Dyslipidemia in Myositis Survey

Primary Objectives: 
To examine the frequency of lipid profile abnormalities in patients with myositis.

Start Date: 2009
Completion Date: 2010

Lead Investigators:

Publications:

  1. Charles-Schoeman C, Amjadi SS, Paulus HE; International Myositis Assessment and Clinical Studies Group. Treatment of dyslipidemia in idiopathic inflammatory myositis: results of the International Myositis Assessment and Clinical Studies Group survey, Clin Rheumatol. 2012 Aug;31(8):1163-8. [Abstract]

IMACS Project V. Identification of a Candidate Core-set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory Myopathies

Primary Objectives:
To develop consensus on a candidate core-set of fitness and strength tests for children and adults with myositis

Start Date: 2013
Completion Date: 2015

Lead Investigators:

Publications:

  1. van der Stap DK, Rider LG, Alexanderson H, Huber AM, Gualano B, Gordon P, van der Net J, Mathiesen P, Johnson LG, Ernste FC, Feldman BM, Houghton KM, Singh-Grewal D, Kutzbach AG, Munters LA, Takken T; International Myositis Assessment and Clinical Studies Group. Proposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory Myopathies. J Rheumatol. 2016 Jan;43(1):169-76. [Abstract]

IMACS Project VII. Development of an Internationally Agreed Minimal Dataset for Juvenile Dermatomyositis (JDM) for Clinical and Research Use

Primary Objectives: 
To develop consensus on minimal elements to include in a JDM dataset to be used for clinical and research purposes.

Start Date: 2014
Completion Date: 2017

Lead Investigators:

Publications:

  1. McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, Williamson PR, Aggarwal A, Christopher-Stine L, Constantin T, Feldman BM, Lundberg I, Maillard S, Mathiesen P, Murphy R, Pachman LM, Reed AM, Rider LG, van Royen-Kerkof A, Russo R, Spinty S, Wedderburn LR, Beresford MW. Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. Ann Rheum Dis. 2018 Feb;77(2):241-250. doi: 10.1136/annrheumdis-2017-212141. Epub 2017 Oct 30. [Abstract]
  2. McCann LJ, Kirkham JJ, Wedderburn LR, Pilkington C, Huber AM, Ravelli A, Appelbe D, Williamson PR, Beresford MW.  Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use.  Trials. 2015 Jun 12;16:268. [Abstract]
  3. McCann LJ, Arnold K, Pilkington CA, Huber AM, Ravelli A, Beard L, Beresford MW, Wedderburn LR. Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research. Pediatr Rheumatol Online J. 2014 Jul 21;12:31. [Abstract]

Ongoing IMACS Research Projects

IMACS Project VI. International Myositis Classification Criteria Project

Primary Objectives: 
To develop new preliminarily validated classification criteria for adult and juvenile dermatomyositis, adult polymyositis and inclusion body myositis.

For further information on the International Myositis Classification Criteria Project, please see Classification Criteria.

Start Date: 2004
Completion Date:
Ongoing

Lead Investigators:

Publications:

  1. Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG; International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017 Dec;76(12):1955-1964. doi: 10.1136/annrheumdis-2017-211468. [Abstract]
  2. Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol. 2017 Dec;69(12):2271-2282. doi: 10.1002/art.40320. [Abstract]
  3. Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, García-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, Lundberg IE; International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open. 2017 Nov 14;3(2):e000507. doi: 10.1136/rmdopen-2017-000507. eCollection 2017. [Abstract]

IMACS Project VIII. IMACS Outcomes Data Repository

Primary Objectives: 
Develop a repository of databases of myositis natural history studies and therapeutic trials that have all collected the IMACS disease activity and damage core set measures, as well as core demographic and clinical data, for use by myositis researchers.

For further information on the IMACS Outcomes Data Repository, including use of the data that has been deposited, please see: IMACS Outcomes Repository Data Use Guidelines.

Start Date: 2004
Completion Date: Ongoing

Lead Investigators:

Publications:

See Project X. ACR-EULAR Project to Revise the Definition of Improvements and Major Clinical Response for Adult and Juvenile Dermatomyositis and Adult Polymyositis

IMACS Project IX. Standards of Treatment for Adults with Myositis and different Phenotypes – STAMP.

Primary Objectives: 
To define standard approaches to treat myositis phenotypes.

Start Date: 2011
Completion Date: Ongoing

Lead Investigators:

Publications:

  1. Tansley S, Shaddick G, Christopher-Stine L, Sharp C, Dourmishev L, Maurer B, Chinoy H, McHugh N. Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences. Clin Exp Rheumatol 2016 May 31. Erratum in: Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1127. [Abstract]

IMACS Project X. ACR-EULAR Project to Revise the Definition of Improvement and Major Clinical Response for Adult and Juvenile Dermatomyositis and Adult Polymyositis

Primary Objectives: 
To develop new response criteria for adult and juvenile dermatomyositis and polymyositis, including criteria for minimal and major response for use as endpoints in myositis therapeutic trials. New response criteria have been developed and validated and endorsed by the American College of Rheumatology and European League Against Rheumatism (see Myositis Response Criteria). In a future phase of the work, the new criteria will be further refined and re-validated using a new clinical trials and studies.

Start Date: 2012
Completion Date: Ongoing

Lead Investigators:

Publications:

  1. Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Magalhaes CS, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, Ruperto N; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2017 May;69(5):911-923. doi: 10.1002/art.40060. [Abstract]
  2. Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, García-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2017 May;69(5):898-910. doi: 10.1002/art.40064. [Abstract]
  3. Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Saad Magalhaes C, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, Ruperto N; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2017 May;76(5):782-791. doi: 10.1136/annrheumdis-2017-211401. [Abstract]
  4. Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, García-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2017 May;76(5):792-801. doi: 10.1136/annrheumdis-2017-211400. [Abstract]
  5. Rider LG, Ruperto N, Pistorio A, Erman B, Bayat N, Lachenbruch PA, Rockette H, Feldman BM, Huber AM, Hansen P, Oddis CV, Lundberg IE, Amato AA, Chinoy H, Cooper RG, Chung L, Danko K, Fiorentino D, García-De la Torre I, Reed AM, Wook Song Y, Cimaz R, Cuttica RJ, Pilkington CA, Martini A, van der Net J, Maillard S, Miller FW, Vencovsky J, Aggarwal R; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation. 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. Rheumatology (Oxford). 2017 Nov 1;56(11):1884-1893. doi: 10.1093/rheumatology/kex226. [Abstract]

IMACS Project XI. Guidelines for Cancer Screening and Follow-up of Myositis Phenotypes

Primary Objectives:
Objectives of this project include derivation/definition of consensus guidelines for cancer screening in patients diagnosed with idiopathic inflammatory myopathies.

Start Date: 2015
Completion Date: Ongoing

Lead Investigators: 

Publications: 
None

IMACS Project XII. Screening, Treatment, and Monitoring of Myositis-Associated Interstitial Lung Disease

Primary Objectives: 
Through the development of a combined retrospective/prospective database, the purpose of this project is to devise consensus guidelines for diagnosis, management, and outcomes assessment in myositis-associated ILD.

Start Date: 2015
Completion Date: Ongoing

Lead Investigators: 

Publications: 
None

IMACS Project XIII. The Role of Rituximab and Mycophenolate Mofetil, without Oral Steroids, in the Treatment of Myositis

Primary Objectives: 
This purpose of this project is to synthesize retrospective experience involving rituximab and mycophenolate mofetil (MMF) combination therapy in the treatment of myositis subsets (including myositis-associated ILD) as a foundation for future clinical trials using rituximab and MMF in the absence of corticosteroids.

Start Date: 2015
Completion Date: Ongoing

Lead Investigators: 

  • David A. Isenberg , M.D., F.R.C.P., M.D.
    ARC Diamond Jubilee Professor of Rheumatology
    d.isenberg@ucl.ac.uk

Publications: 
None

Back
to Top